The nucleoside analogue, 2',3'-dideoxycytidine (ddC), is a potent inhibitor of HIV replication, and AIDS patients receiving ddC experience clinical improvement without significant hematologic toxicity. Repeated ddC administration (1,000 mg/kg per day) for 13 wk produces an increased incidence of thymic lymphoma in B6C3F1 mice. Previous studies reveal a common link between chemically induced and genetically associated models of mouse thymic lymphoma that involves a defect in a subpopulation of primitive hematopoietic progenitor cells. This defect is characterized by suppression of a subpopulation of IL-3-responsive cells and ablation of stem cell factor synergy with GM-CSF. The present study was undertaken to ascertain whether ddC produces the same pattern of bone marrow toxicity in mice, and whether this effect is observed in rat and human bone marrow. ddC exposure in vivo and in vitro produced a select suppression of murine CFU identical to that previously described for other models of mouse thymic lymphoma. In contrast, this selective CFU suppression was not observed in rat and human bone marrow or in CD34+ cells. These studies suggest that the mouse may not be a good predictive model for ddC hematotoxicity in humans and that susceptibility to the development of thymic lymphoma may be unique to the mouse. (J. Clin. Invest. 1995. 95:2777-2782 
Introduction
The nucleoside analogue, 2',3'-dideoxycytidine (ddC)l is approved for treatment of HIV positive patients. ddC interferes with HIV replication by inhibiting reverse transcriptase (1, 2) , and AIDS patients receiving ddC experience clinical improve-ment with less hematologic toxicity than associated with the use of zidovudine (3 '-azido-2 ',3 '-dideoxythymidine) (AZT) (3, 4) . A treatment-related increase in lymphoma has not been reported. However, in two separate studies, high dose administration of ddC, 1,000 mg/kg per day, for three months to mice by gavage resulted in a significant incidence of thymic lymphoma/leukemia (TL), anemia, and thymic atrophy (National Toxicology Program. 1993. Subchronic toxicity study of 2 ',3 '-dideoxycytidine (ddC) in female B6C3F1 mice. Southern Research Institute Study A19-SCM-3) (5) .
The pathogenesis of TL is virtually identical in radiation, chemical and genetic mouse models, invoking a paradigm that includes the requirement for a "preleukemic event" in bone marrow (BM), accompanied by a macrocytic anemia, thymic hypoplasia and the development of lymphoma in the thymus (5) (6) (7) (8) (9) (10) (11) (12) .
We have previously identified a distinct subpopulation of stem cell factor (SCF) -dependent/LL-3-responsive hematopoietic progenitor cells (HPC) in the mouse that is uniquely susceptible to functional suppression by murine leukemogens, such as 1,3-butadiene (13) and y-irradiation (Irons, R. D., S. C. Lee, and W. S. Stillman, manuscript in preparation). This subpopulation of HPC is identical to that constitutively missing in mice bearing W or Sl mutations that spontaneously develop TL (13) . Mice with mutations at the SI and W locus demonstrate complementary defects for SCF, SI mice are deficient in SCF (14) , and W mice lack a functional analogous receptor, C-kit (15, 16) . Taken together, these results suggest that the genetic or functional suppression of this subpopulation of primitive hematopoietic cells represents the early bone marrow lesion common to chemical, radiation, and genetic models of murine TL leukemogenesis.
Herein, we examined whether ddC exposure in vivo and in vitro produces the same lesion as described above. Moreover, in order to determine if there are species-specific differences in susceptibility to ddC, we compared the effects of ddC on unpurified rat and unpurified and CD34-enriched human bone marrow cells. The results of these studies demonstrate that ddC targets the same population of primitive murine HPC as other murine leukemogens. In contrast, no selective suppression of clonogenic response is observed in rat or human bone marrow cells. (-) IL-3 (1 ng/ml); (B) (-) rGM-CSF (2 ng/ml); (-) rGM-CSF (2 ng/ml) + rSCF (10 ng/ml). Error bars indicate 1 SEM for five cultures and are omitted when they are smaller than the symbol. * Significant decrease compared with controls not cultured with ddC (P 0.05).
Modified Iscove's medium, L-glutamine, penicillin/streptomycin solution and PBS were purchased from GIBCO BRL, (Gaithersburg, MD Figure 5 . Recombinant rGM-CSF (2 ng/ml) with or without rSCF (2 ng/ml) and IL-3 (1 ng/ml) stimulated CFU of BM from B6C3F1 mice killed 2 h after single administration of ddC by gavage. Error bars indicate 1 SEM for five cultures from each of three animals. * Significant decrease compared with controls given vehicle only (P s 0.05). medium containing 10-20% FBS, 100 mg/ml streptomycin, 100 U/ml penicillin, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 1.2% (wt/ vol) methyl cellulose, and recombinant cytokines. Each cytokine was used at concentrations experimentally determined to produce maximal colony formation. All cultures were maintained at 37TC in 5% Co2. Results ddC cultured with B6C3FJ, C57BL/6, or CD-I murine bone marrow cells in vitro produces an identical suppression of clonogenic response as described for other mouse leukemogens. B6C3F1 mouse bone marrow cells cultured with ddC in vitro results in a suppression of clonogenic response in a subpopulation of IL-3 responsive cells (Fig. 1 A) , and abrogation of SCF synergy with GM-CSF (Fig. 1 B) . The identical suppression of CFU is observed when murine HPC are pretreated with epoxybutene, a metabolite of the prototype murine leukemogen, 1,3-butadiene (13) . Murine BM pretreated with epoxybutene is completely unresponsive to the effects of ddC, confirming that ddC targets the same subpopulation of clonogenic cells (Fig. 2) . Moreover, ddC pretreatment of bone marrow from W/Wv and Sl/Sld mice does not suppress IL-3 (Fig. 3) or alter GM-CSF response (data not shown), indicating that the subpopulation of cells targeted by ddC is the same subpopulation of primitive hematopoietic cells previously demonstrated to be absent in these genetic models (13) .
We also compared the relative susceptibility of HPC to the Error bars indicate 1 SEM for five cultures and are omitted when they are smaller than the symbol. * Significant decrease compared with controls not cultured with ddC (P < 0.05).
it is likely that they are related to the pharmacodynamics of ddC and not intrinsic differences in target cell-specific metabolism or susceptibility. ddC cultured with CD rat bone marrow cells in vitro does not affect CFU response. In contrast to mice, rats are resistant )P . , -to the development of lymphoma/leukemia, and do not develop 0 500 1000 1500 2000 the disease following chronic exposure to butadiene (17, 18) or radiation ( 19 (Fig. 7) .
Three animals (n = 5 cultures per animal) were examddC cultured with nonadherent human bone marrow or Jose.
CD34+ cells in vitro produces no selective suppression of clonogenic response. The CD34+ cell population contains all clonogenic cells identified in human BM, including both long term ,ffects of ddC in vitro using BM from C57BL/ 6 and short term repopulating cells (20) , and is markedly enriched ce. Fig. 4 summarizes the effects of ddC exposure for primitive HPC that are responsive to SCF synergism with ie three different strains of mice. Specific suppres-GM-CSF. This corresponds to the cell population targeted by J was observed in each strain at 10-18 M ddC. ddC in mouse bone marrow. A total of 11 experiments were nonspecific cytotoxicity was evident in each strain conducted using human bone marrow cells; 4 used mononuclear LC (Fig. 1, data Fig. 8 , with all the data from e were given various doses of ddC by gavage and these experiments presented in Fig. 9 . ddC pretreatment does 2 h later for IL-3, GM-CSF, and GM-CSF/SCF not result in selective suppression of SCF-dependent/IL-3 relonogenic response. The identical pattern of supsponsive HPC in either nonadherent or CD34+ enriched human characterizes in vitro exposure of BM to ddC and BM cells. Nonspecific cytotoxicity is consistently observed in leukemogens is observed in the 1,000 and 2,000 nonadherent cells from mice, rats and humans incubated with lose groups (Fig. 5) Discussion is involved in the targeting of these cells. Taken together, these results suggest that suppression of this subpopulation of primitive HPC represents the "preleukemic bone marrow lesion" common to chemical, radiation, and spontaneous models of murine leukemogenesis and provide evidence that targeting of this cell population is an early obligatory event in the development of murine TL. There is growing evidence to suggest that species differences exist in the organization of the hematopoietic stem cell compartment, particularly with respect to the stage at which primitive HPC become restricted to a particular differentiation paradigm. In contrast to primitive murine HPC that require IL-3 or SCF for survival, comparable human HPC appear to be supported in Go by IL-3 or GM-CSF but not SCF (26) (27) (28) . It is apparent that these differences coincide with the observed susceptibility of an early SCF-responsive subpopulation of murine HPC, and that species differences in differentiation of early HPC play a major role in conferring susceptibility to TL development in the mouse. Moreover, because susceptibility of primitive HPC to drug suppression is observed only in the mouse, murine TL does not appear to be an appropriate biologic model for hazard identification in humans.
